title: Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms.
abstract: Based on the implication of increased muscarinic ACh activity in the production of negative symptoms, the association of decreasing cholinergic activity with positive symptoms, and the covariance of positive and negative symptoms in the psychotic phase of schizophrenia, a model of (DA) dopaminergic/(ACh) cholinergic interactions in schizophrenia was recently formulated. It suggests that DA/ACh balance is of central importance in schizophrenic pathophysiology and that muscarinic ACh activity increases in an attempt to maintain this balance in the face of increasing DA activity that occurs in the psychotic phase of the illness. The model further suggests that the muscarinic system exerts a damping influence on the emergence of positive symptoms associated with DA hyperactivity, but that this compensatory increase in muscarinic activity is accompanied by an intensification of negative symptoms. In the present study, we tested two important postulates of this model. We tested the prediction that muscarinic activity is increased in schizophrenia by comparing the effect of biperiden, an antimuscarinic M-1 agent, on REM latency in 12 drug-free schizophrenic inpatients and matched normal controls. We found that biperiden caused a smaller increase in REM latency in schizophrenic patients, suggesting that muscarinic activity is increased in schizophrenia. We tested the prediction that an anticholinergic agent would increase positive symptoms and decrease negative symptoms by studying the effect of 8 mg of biperiden/day for 2 days on positive and negative symptoms (assessed by the BPRS) in 30 medication-free schizophrenic inpatients.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Psychiatry, University of Michigan Medical Center, Ann Arbor 48109-0120.
authors.forename: R
authors.initials: R
authors.lastname: Tandon
authors.forename: J E
authors.initials: JE
authors.lastname: Shipley
authors.forename: J F
authors.initials: JF
authors.lastname: Greden
authors.forename: N A
authors.initials: NA
authors.lastname: Mann
authors.forename: W H
authors.initials: WH
authors.lastname: Eisner
authors.forename: J A
authors.initials: JA
authors.lastname: Goodson
mesh_terms: D000328:Adult; D001143:Arousal / Q000187:drug effects / Q000502:physiology*; D001712:Biperiden / Q000008:administration & dosage*; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D011930:Reaction Time / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D012894:Sleep Stages / Q000187:drug effects; D012895:Sleep, REM / Q000187:drug effects
chemical_list: D011976:Receptors, Muscarinic; D001712:Biperiden